There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.
Transcript:
Do you think we will be seeing more mandatory payment models as opposed to voluntary models? Will we ever see exclusively mandatory payment models?
I think we will begin to see mandatory models. As I think about the evolution of the movement from fee-for-service to value-based care, from my perspective, it makes sense to start in a place where the providers have no risk and everybody has an opportunity to learn together how to create success in these models. They work best and everybody learns best, if the partners who are engaged in the models are those who have the propensity and the inclination and the willingness to change. Then, once the success is proven, to be able to share with other other partners who may come into the model, I think as that progression happens, and success is achieved, we'll begin to see more mandatorily required episodes in models. But I don't think that's going to happen immediately in any broad scale. As to the question around whether I think there will ever be all mandatory, I think absolutely not. I don't even think there will ever be all value-based care, I think there will remain some fee-for-service. I am a believer that we can craft a value-based model around just about anything, as long as you have a construct and everybody agrees on what the criteria is. But I think there will still always be some pieces of delivery that are going to be a fee-for-service.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More